Imunon (IMNN) Investor presentation summary

Investment highlights and clinical strategy

• IMNN-001 is a first-in-class IL-12 DNA immunotherapy for newly diagnosed advanced ovarian cancer, showing unprecedented efficacy and a strong safety profile in Phase 2 trials.

• The registrational Phase 3 study is underway, targeting 500 patients with overall survival as the primary endpoint and two interim analyses for early stopping and BLA filing.

• IMNN-001 has received FDA Fast Track and Orphan Drug status in the US and EU, with cGMP manufacturing in place for both clinical and future commercial supply.

• Ovarian cancer remains a multi-billion-dollar unmet need, with high recurrence and mortality rates despite decades of standard care.

Mechanism of action and clinical differentiation

• IMNN-001 delivers IL-12 locally via intraperitoneal infusion, transforming the tumor microenvironment from immunologically "cold" to "hot" and activating both innate and adaptive immunity.

• Local delivery avoids systemic toxicities seen with recombinant IL-12, enabling higher, durable concentrations at the tumor site and a favorable safety profile.

• IMNN-001 reduces immunosuppressive biomarkers and increases cytotoxic T-cell and dendritic cell infiltration in tumors.

Clinical data and efficacy

• Phase 2 OVATION-2 trial showed a median overall survival improvement of 14.7 months over standard of care (45.1 vs. 30.4 months), with a trend toward statistical significance.

• In PARPi maintenance-treated patients, IMNN-001 improved median OS by 24.2 months (65.6 vs. 41.4 months).

• Consistent benefit was observed across all endpoints and pre-specified subgroups, including progression-free survival and surgical response.

• No systemic dose-limiting toxicities or cytokine release syndrome were observed; most common adverse events were manageable.